Print | Share | Contact Us | Search:


Date
Title (click to read)


Jun 17, 2013
Initial Findings from PARADOX, Largest and Most Comprehensive Research Analyzing the Burden of Hypoparathyroidism, Reveals Collection of Nearly 40 Physical, Cognitive, Emotional Symptoms
Jun 17, 2013
Findings Presented at ENDO 2013 Support Therapeutic Potential of Natpara® as Parathyroid Hormone Replacement Therapy in Patients with Hypoparathyroidism
Jun 14, 2013
NPS Pharmaceuticals’ President and CEO Dr. Francois Nader Receives Ernst & Young Entrepreneur Of The Year® 2013 Award in New Jersey
Jun 5, 2013
NPS Pharmaceuticals to Present Data from Natpara™ REPLACE Study and PARADOX Study at ENDO 2013, The Endocrine Society’s 95th Annual Meeting
May 31, 2013
NPS Pharmaceuticals Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day


News Release Archive

Notice to Readers
The reports filed by NPS with the Securities and Exchange Commission and the news releases issued by NPS and posted on this website are current only as of the dates on which they were filed or issued by NPS. Therefore, the contents of these reports and releases can become outdated. We make no commitment, and disclaim any duty, to update these reports and releases. We do not warrant the accuracy or completeness of these materials or the reliability of any advice, opinion, statement or other information displayed or distributed through the website. Readers acknowledge that any reliance on these reports, releases, advice, opinions, statements, or information is at the reader's sole risk.


Stay informed
To stay apprised of NPS Pharmaceuticals press releases, financial reports and SEC filings as they are posted, sign up for Financial Alerts or SEC Alerts via email notification.